AN ACT REQUIRING BRAND NAME PRESCRIPTION DRUG MANUFACTURERS TO PROVIDE SAMPLES OF BRAND NAME DRUGS TO GENERIC PRESCRIPTION DRUG MANUFACTURERS.
To promote competition in the prescription drug market by allowing developers of generic drugs and biosimilar products to obtain reference samples.
Introduced by:General Law Committee
|New today||2-4 days old||5 days & older|
Co-sponsors for Amendment LCO:
|4/7/2022||Referred by Senate to Committee on Judiciary|
|3/30/2022||(LCO)||File Number 214|
|3/30/2022||Senate Calendar Number 170|
|3/30/2022||Favorable Report, Tabled for the Calendar, Senate|
|3/30/2022||(LCO)||Reported Out of Legislative Commissioners' Office|
|3/24/2022||(LCO)||Referred to Office of Legislative Research and Office of Fiscal Analysis 03/29/22 5:00 PM|
|3/16/2022||(LCO)||Filed with Legislative Commissioners' Office|
|2/25/2022||Public Hearing 03/01|
|2/24/2022||Referred to Joint Committee on General Law|
Co-sponsors of SB-188
Sen. Martin M. Looney, 11th Dist.
Sen. Saud Anwar, 3rd Dist.
Rep. Michael A. Winkler, 56th Dist.